Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Remdesivir: First Approval
Yvette N. Lamb
Drugs (2020) Vol. 80, Iss. 13, pp. 1355-1363
Open Access | Times Cited: 248

Showing 1-25 of 248 citing articles:

Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay
Anoop Narayanan, M. Narwal, Sydney A. Majowicz, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 181
SARS-CoV-2 and nervous system: From pathogenesis to clinical manifestation
Kiandokht Keyhanian, Raffaella Pizzolato Umeton, Babak Mohit, et al.
Journal of Neuroimmunology (2020) Vol. 350, pp. 577436-577436
Open Access | Times Cited: 140
Antivirals with common targets against highly pathogenic viruses
Lu Lu, Shan Su, Haitao Yang, et al.
Cell (2021) Vol. 184, Iss. 6, pp. 1604-1620
Open Access | Times Cited: 125
Therapeutic potential of pyrrole and pyrrolidine analogs: an update
N. Jeelan Basha, S. M. Basavarajaiah, K. Shyamsunder
Molecular Diversity (2022) Vol. 26, Iss. 5, pp. 2915-2937
Open Access | Times Cited: 123
A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases
Siqin He, Jiajia Gui, Kun Xiong, et al.
Journal of Nanobiotechnology (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 119
Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 82
Recent Advances in Covalent Drug Discovery
D. M. Schaefer, Xinlai Cheng
Pharmaceuticals (2023) Vol. 16, Iss. 5, pp. 663-663
Open Access | Times Cited: 45
Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects
Giuseppe Lisco, Anna De Tullio, Emilio Jirillo, et al.
Journal of Endocrinological Investigation (2021) Vol. 44, Iss. 9, pp. 1801-1814
Open Access | Times Cited: 100
Computational molecular docking and virtual screening revealed promising SARS-CoV-2 drugs
Maryam Hosseini, Wanqiu Chen, Daliao Xiao, et al.
Precision Clinical Medicine (2021) Vol. 4, Iss. 1, pp. 1-16
Open Access | Times Cited: 99
The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies
Anastassios C. Papageorgiou, Imran Mohsin
Cells (2020) Vol. 9, Iss. 11, pp. 2343-2343
Open Access | Times Cited: 88
Identification of natural compounds as SARS-CoV-2 entry inhibitors by molecular docking-based virtual screening with bio-layer interferometry
Dingqi Zhang, Sami Hamdoun, Ruihong Chen, et al.
Pharmacological Research (2021) Vol. 172, pp. 105820-105820
Open Access | Times Cited: 78
Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.
John G. Rizk, Donald N. Forthal, Kamyar Kalantar‐Zadeh, et al.
Drug Discovery Today (2020) Vol. 26, Iss. 2, pp. 593-603
Open Access | Times Cited: 77
Animal models for SARS-CoV-2
Chung-Young Lee, Anice C. Lowen
Current Opinion in Virology (2021) Vol. 48, pp. 73-81
Open Access | Times Cited: 66
Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: In Vitro Activity against SARS-CoV-2 and Potential Mechanisms
Ana C. Puhl, Ethan J. Fritch, Thomas R. Lane, et al.
ACS Omega (2021) Vol. 6, Iss. 11, pp. 7454-7468
Open Access | Times Cited: 65
Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy
Mona Sadat Mirtaleb, Amir Hossein Mirtaleb, Hassan Nosrati, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 138, pp. 111518-111518
Open Access | Times Cited: 61
The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies
Dang The Hung, Suhaib Ghula, Jeza Muhamad Abdul Aziz, et al.
International Journal of Infectious Diseases (2022) Vol. 120, pp. 217-227
Open Access | Times Cited: 52
Sulfobutylether-β-cyclodextrin: A functional biopolymer for drug delivery applications
Chandrakantsing V. Pardeshi, Rucha V Kothawade, Ashwini R Markad, et al.
Carbohydrate Polymers (2022) Vol. 301, pp. 120347-120347
Closed Access | Times Cited: 44
Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro
Sheli R. Radoshitzky, Patrick L. Iversen, Xianghan Lu, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 35
Antiviral PROTACs: Opportunity borne with challenge
Jinsen Liang, Yihe Wu, Ke Lan, et al.
Cell Insight (2023) Vol. 2, Iss. 3, pp. 100092-100092
Open Access | Times Cited: 34
Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2
Mohamed S. Bekheit, Siva S. Panda, Adel S. Girgis
European Journal of Medicinal Chemistry (2023) Vol. 252, pp. 115292-115292
Open Access | Times Cited: 26
Asymmetric Synthesis of US-FDA Approved Drugs over Five Years (2016–2020): A Recapitulation of Chirality
T. N. Rekha, Dongyun Shin
Pharmaceuticals (2023) Vol. 16, Iss. 3, pp. 339-339
Open Access | Times Cited: 24
Synthesis and examination of 1,2,4‐triazine‐sulfonamide hybrids as potential inhibitory drugs: Inhibition effects on AChE and GST enzymes in silico and in vitro conditions
Przemysław Rozbicki, Ercan Oğuz, Ewa Wolińska, et al.
Archiv der Pharmazie (2024) Vol. 357, Iss. 9
Open Access | Times Cited: 13
Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control
Shen Wang, Wujian Li, Zhenshan Wang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 10
The combination of pleconaril, rupintrivir, and remdesivir efficiently inhibits enterovirus infections in vitro, delaying the development of drug-resistant virus variants
Aleksandr Ianevski, Irene Trøen Frøysa, Hilde Lysvand, et al.
Antiviral Research (2024) Vol. 224, pp. 105842-105842
Open Access | Times Cited: 9
Transformative Approaches in SARS-CoV-2 Management: Vaccines, Therapeutics and Future Direction
Ankita Saha, Shweta Choudhary, Priyanshu Walia, et al.
Virology (2025) Vol. 604, pp. 110394-110394
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top